{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:35:52Z","timestamp":1769168152131,"version":"3.49.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1007\/s11920-004-0020-1","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T21:23:41Z","timestamp":1180733021000},"page":"339-346","source":"Crossref","is-referenced-by-count":16,"title":["Recent advances in the treatment of opiate addiction"],"prefix":"10.1007","volume":"6","author":[{"given":"Paul J.","family":"Fudala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George W.","family":"Woody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"20_CR1","unstructured":"US v Moy 241 US 394 (1916)."},{"key":"20_CR2","unstructured":"US v Doremus 249 US 86, 94 (1919)."},{"key":"20_CR3","unstructured":"Narcotic Addict Treatment Act, Pub. L. No. 93-281 (1974)."},{"key":"20_CR4","unstructured":"Narcotic Addict Treatment Act, Pub. L. No. 93-281 (1974). The Drug Addiction Treatment Act represents a major policy shift in addiction treatment and is the mechanism by which qualified physicians may dispense and prescribe certain approved Schedule III, IV, and V narcotic medications for opioid addiction treatment in settings other than traditional opioid treatment programs."},{"key":"20_CR5","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0376-8716(03)00055-3","volume":"70","author":"JH Jaffe","year":"2003","unstructured":"Jaffe JH, O\u2019Keeffe CO: From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend 2003, 70(suppl):S3-S11.","journal-title":"Drug Alcohol Depend"},{"key":"20_CR6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00003495-197917020-00001","volume":"17","author":"RC Heel","year":"1979","unstructured":"Heel RC, Brogden RN, Speight TM, Avery GS: Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs 1979, 17:81\u2013110.","journal-title":"Drugs"},{"key":"20_CR7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archpsyc.1978.01770280111012","volume":"35","author":"DR Jasinski","year":"1978","unstructured":"Jasinski DR, Pevnick JS, Griffith JD: Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978, 35:501\u2013516.","journal-title":"Arch Gen Psychiatry"},{"key":"20_CR8","first-page":"517","volume":"197","author":"WR Martin","year":"1976","unstructured":"Martin WR, Eades CG, Thompson JA, et al.: The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976, 197:517\u2013532.","journal-title":"J Pharmacol Exp Ther"},{"key":"20_CR9","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1016\/0024-3205(81)90529-4","volume":"29","author":"JW Villiger","year":"1981","unstructured":"Villiger JW, Taylor KM: Buprenorphine: characteristics of binding sites in the rat central nervous system. Life Sci 1981, 29:2699\u20132708.","journal-title":"Life Sci"},{"key":"20_CR10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0024-3205(83)90474-5","volume":"33","author":"W Sad\u00e9e","year":"1983","unstructured":"Sad\u00e9e W, Richards ML, Grevel J, Rosenbaum JS: In vivo characterization of four types of opioid binding sites in rat brain. Life Sci 1983, 33:187\u2013189.","journal-title":"Life Sci"},{"key":"20_CR11","first-page":"157","volume":"223","author":"W Sad\u00e9e","year":"1982","unstructured":"Sad\u00e9e W, Rosenbaum JS, Herz A: Buprenorphine: differential interaction with opiate receptor subtypes in vivo. J Pharmacol Exp Ther 1982, 223:157\u2013162.","journal-title":"J Pharmacol Exp Ther"},{"key":"20_CR12","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0196-9781(00)00252-7","volume":"21","author":"P Bloms-Funke","year":"2000","unstructured":"Bloms-Funke P, Gillen C, Schuettler AJ, Wnendt S: Agonistic effects of the opioid buprenorphine on the nociceptin\/OFQ receptor. Peptides 2000, 21:1141\u20131146.","journal-title":"Peptides"},{"key":"20_CR13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0014-2999(99)00460-4","volume":"378","author":"KO Lee","year":"1999","unstructured":"Lee KO, Akil H, Woods JH, Traynor JR: Differential binding properties of oripavines at cloned mu- and delta-opioid receptors. Eur J Pharmacol 1999, 378:323\u2013330.","journal-title":"Eur J Pharmacol"},{"key":"20_CR14","first-page":"19","volume-title":"Buprenorphine: Combatting Drug Abuse with a Unique Opioid","author":"RB Rothman","year":"1995","unstructured":"Rothman RB, Qi N, Heng X: Buprenorphine: A review of the binding literature. In Buprenorphine: Combatting Drug Abuse with a Unique Opioid. Edited by Cowan A, Lewis JW. New York: Wiley-Liss; 1995:19\u201329."},{"key":"20_CR15","unstructured":"Anonymous: Drugs approved for opiate dependence. FDA Consum 2003, 37:6."},{"key":"20_CR16","unstructured":"Substance Abuse and Mental Health Services Administration. Opioid drugs in maintenance and detoxification treatment of opiate addiction; addition of buprenorphine and buprenorphine combination to list of approved opioid treatment medications. Interim final rule. Fed Regist 2003, 68:27937\u201327939."},{"key":"20_CR17","unstructured":"Sustance Abuse and Mental Health Services Administration. Physician Locator. http:\/\/buprenorphine.samhsa.gov. Accessed May 1, 2004."},{"key":"20_CR18","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1001\/jama.290.6.731","volume":"290","author":"B Vastig","year":"2003","unstructured":"Vastig B: In-office opiate treatment \"not a panacea.\" Physicians slow to embrace therapeutic option. J Am Med Assoc 2003, 290:731\u2013735.","journal-title":"J Am Med Assoc"},{"key":"20_CR19","unstructured":"Sustance Abuse and Mental Health Services Administration. Physician Waiver Qualifications. http:\/\/buprenorphine.samhsa. gov. Accessed May 1, 2004. This web link describes the policy and procedures related to the obtaining of the waiver which allows qualifying physicians to use buprenorphine and buprenorphine\/naloxone (and other FDAapproved Schedule III, IV, or V narcotic medications as they become available) for office-based opiate addiction treatment."},{"key":"20_CR20","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1001\/jama.1993.03500150065028","volume":"269","author":"AT McLellan","year":"1993","unstructured":"McLellan AT, Arndt IO, Metzger DS, et al.: The effects of psychosocial services on substance abuse treatment. J Am Med Assoc 1993, 269:1953\u20131959.","journal-title":"J Am Med Assoc"},{"key":"20_CR21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","volume":"9","author":"AT McLellan","year":"1992","unstructured":"McLellan AT, Kushner H, Metzger D, et al.: The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992, 9:199\u2013213.","journal-title":"J Subst Abuse Treat"},{"key":"20_CR22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1037\/0893-164X.15.1.4","volume":"15","author":"SF Butler","year":"2001","unstructured":"Butler SF, Budman SH, Goldman RJ et al.: Initial validation of a computer-administered Addiction Severity Index: the ASIMV. Psychol Addict Behav 2001, 15:4\u201312.","journal-title":"Psychol Addict Behav"},{"key":"20_CR23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0740-5472(98)00047-6","volume":"17","author":"D Carise","year":"1999","unstructured":"Carise D, McLellan AT, Gifford LS, Kleber HD: Developing a national addiction treatment information system: An introduction to the Drug Evaluation Network System. J Subst Abuse Treat 1999, 17:67\u201377.","journal-title":"J Subst Abuse Treat"},{"key":"20_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00952999809001695","volume":"24","author":"MA Chutuape","year":"1998","unstructured":"Chutuape MA, Silverman K, Stitzer ML: Survey assessment of methadone treatment services as reinforcers. Am J Drug Alcohol Abuse 1998, 24:1\u201316.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"20_CR25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0005-7894(96)80034-7","volume":"27","author":"M Kidorf","year":"1996","unstructured":"Kidorf M, Stitzer ML: Contingent use of take-homes and splitdosing to reduce illicit drug use of methadone patients. Behav Ther 1996, 27:41\u201351.","journal-title":"Behav Ther"},{"key":"20_CR26","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0306-4603(02)00297-6","volume":"27","author":"ST Higgins","year":"2002","unstructured":"Higgins ST, Alessi SM, Dantona RI: Voucher-based incentives: a substance abuse treatment innovation. Addict Behav 2002, 27:887\u2013910.","journal-title":"Addict Behav"},{"key":"20_CR27","unstructured":"Epidemiologic trends in drug abuse. Proceedings of the Community Epidemiology Work Group, Volume 1, June, 2003. Bethesda: United States Department of Health and Human Services, National Institutes of Health; 2003"},{"key":"20_CR28","unstructured":"OxyContin\u00ae: Prescription drug abuse. CSAT Treatment Advisory April, 2001. Rockville: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration; 2001."},{"key":"20_CR29","unstructured":"Office of National Drug Control Policy. Pulse Check: Trends in Drug Abuse November 2001 - Special Topic Synthetic Opioids. Washington, DC: Office of National Drug Control Policy; 2001. http:\/\/ www.whitehousedrugpolicy.gov\/publications\/drugfact\/ pulsechk\/fall2001\/special.html Accessed May 12, 2004."},{"key":"20_CR30","unstructured":"Office of National Drug Control Policy. Pulse Check: Trends in Drug Abuse April 2002 - Diverted Synthetic Opioids. Washington, D.C.: Office of National Drug Control Policy; 2002. http:\/\/ www.whitehousedrugpolicy.gov\/publications\/drugfact\/ pulsechk\/apr02\/synthetic_opiods.html Accessed May 12, 2004."},{"key":"20_CR31","unstructured":"Office of National Drug Control Policy. Pulse Check: Trends in Drug Abuse, November 2002 - Diverted Synthetic Opioids. Washington, DC: Office of National Drug Control Policy; 2002. http:\/\/www.whitehousedrugpolicy. gov\/publications\/drugfact\/pulsechk\/nov02\/ div_synth_opiods.html Accessed May 12, 2004."},{"key":"20_CR32","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). Strategies for Developing Treatment Programs for People With Co-Occurring Substance Abuse and Mental Disorders. SAMHSA Publication No. 3782. Rockville: SAMHSA; 2003."},{"key":"20_CR33","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0306-4603(02)00297-6","volume":"27","author":"ST Higgins","year":"2002","unstructured":"Higgins ST, Alessi SM, Dantona RL: Voucher-based incentives: a substance abuse treatment innovation. Addict Behav 2002, 27:887\u2013910.","journal-title":"Addict Behav"},{"key":"20_CR34","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1037\/0022-006X.70.2.398","volume":"70","author":"NM Petry","year":"2002","unstructured":"Petry NM, Marftin B: Low-cost contingency management for treating cocaine and opioid-abusing methadone patients. J Consult Clin Psychol 2002, 70:398\u2013405.","journal-title":"J Consult Clin Psychol"},{"key":"20_CR35","unstructured":"National Institute on Drug Abuse. NIDA Community Drug Alert Bulletin - Hepatitis. Rockville: National Institute on Drug Abuse; 2000. http:\/\/www.drugabuse.gov\/HepatitisAlert\/HepatitisAlert. html#Anchor-Injection-17780 Accessed May 12, 2004."},{"key":"20_CR36","first-page":"9","volume":"16","author":"J Thomas","year":"2001","unstructured":"Thomas J: Drug injectors sharing cookers and cotton increase their risk of hepatitis C. NIDA Notes 16:9\u201311, 2001.","journal-title":"NIDA Notes"},{"key":"20_CR37","unstructured":"Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington DC: American Psychiatric Association; 2000."},{"key":"20_CR38","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.291.15.1887","volume":"291","author":"EV Nunes","year":"2004","unstructured":"Nunes EV, Levin FR: Treatment of depression in patients with alcohol or other drug dependencies. J Am Med Assoc 2004, 291:1887\u20131896. This review provides evidence that antidepressant pharmacotherapy helps relieve depression in patients with methadone dependence.","journal-title":"J Am Med Assoc"},{"key":"20_CR39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1300\/J069v17n03_07","volume":"17","author":"BJ Mason","year":"1998","unstructured":"Mason BJ, Kocsis JH, Melia D, et al.: Psychiatric comorbidity in methadone maintained patients. J Addict Dis 1998, 17:75\u201389.","journal-title":"J Addict Dis"},{"key":"20_CR40","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/archpsyc.61.4.361","volume":"61","author":"BF Grant","year":"2004","unstructured":"Grant BF, Stinson FS, Dawson DA, et al.: Co-occurrence of 12- month alcohol and drug use disorders and personality disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004, 61:361\u2013368. This article shows that in addition to antisocial personality disorder, other personality disorders are found with increased prevalence among patients with substance abuse disorders.","journal-title":"Arch Gen Psychiatry"},{"key":"20_CR41","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/archpsyc.1985.01790340059009","volume":"42","author":"GE Woody","year":"1985","unstructured":"Woody GE, McLellan AT, Luborsky L, et al.: Sociopathy and psychotherapy outcome. Arch Gen Psychiatry 1985, 42:1081\u20131086.","journal-title":"Arch Gen Psychiatry"},{"key":"20_CR42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1037\/h0080151","volume":"66","author":"RC Kessler","year":"1996","unstructured":"Kessler RC, Nelson CB, McGonagle KA, et al.: The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry 1996, 66:17\u201331.","journal-title":"Am J Orthopsychiatry"},{"key":"20_CR43","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1001\/jama.286.14.1715","volume":"286","author":"C Weisner","year":"2001","unstructured":"Weisner C, Mertens J, Parthasarathy S, et al.: Integrating primary medical care with addiction treatment: A randomized controlled trial. J Am Med Assoc 2001, 286:1715\u20131723.","journal-title":"J Am Med Assoc"},{"key":"20_CR44","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0376-8716(01)00208-3","volume":"663","author":"SL Batki","year":"2002","unstructured":"Batki SL, Gruber VA, Bradley JM, et al.: A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. Drug Alcohol Depend 2002, 663:283\u2013293.","journal-title":"Drug Alcohol Depend"},{"key":"20_CR45","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2105\/AJPH.84.2.207","volume":"84","author":"A Umbricht-Schneiter","year":"1994","unstructured":"Umbricht-Schneiter A, Ginn DH, Pabst KM, et al.: Providing medical care to methadone clinic patients: Referral vs. onsite care. Am J Public Health 1994, 84:207\u2013210.","journal-title":"Am J Public Health"},{"key":"20_CR46","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/0306-4603(96)00042-1","volume":"21","author":"GA Marlatt","year":"1996","unstructured":"Marlatt GA: Harm reduction: Come as you are. Addict Behav 1996, 21:779\u2013788.","journal-title":"Addict Behav"},{"key":"20_CR47","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/bmj.327.7410.310","volume":"327","author":"W Brink van den","year":"2003","unstructured":"van den Brink W, Hendriks VM, Blanken P, et al.: Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. Br Med J 2003, 327:310\u2013316.","journal-title":"Br Med J"},{"key":"20_CR48","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(01)06529-1","volume":"358","author":"J Rehm","year":"2001","unstructured":"Rehm J, Gschwend P, Steffen T, et al.: Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet 2001, 358:1417\u20131420.","journal-title":"Lancet"},{"key":"20_CR49","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2105\/AJPH.85.8_Pt_1.1059","volume":"85","author":"P Reuter","year":"1995","unstructured":"Reuter P, Caulkins JP: Redefining the goals of national drug policy: Recommendations from a working group. Am J Publ Health 1995, 85:1059\u20131063.","journal-title":"Am J Publ Health"},{"key":"20_CR50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/10826089909035633","volume":"34","author":"H Kalant","year":"1999","unstructured":"Kalant H: Differentiating drugs by harm potential: The rational versus the feasible. Subst Use Misuse 1999, 34:25\u201334.","journal-title":"Subst Use Misuse"},{"key":"20_CR51","volume-title":"Preventing HIV Transmission: The Role of Sterile Needles and Bleach","year":"1995","unstructured":"Preventing HIV Transmission: The Role of Sterile Needles and Bleach. Edited by Normand J, Vlahov D, Moses L. Washington DC: National Academy Press; 1995."},{"key":"20_CR52","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00002030-200003310-00015","volume":"4","author":"RN Bluthenthal","year":"2000","unstructured":"Bluthenthal RN, Kral AH, Gee L, et al.: The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS 2000, 4:605\u2013611.","journal-title":"AIDS"},{"key":"20_CR53","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/BF02351502","volume":"76","author":"SA Strathdee","year":"1999","unstructured":"Strathdee SA, Celentano DD, Shah N, et al.: Needle-exchange attendance and health care utilization promote entry into detoxification. J Urban Health 1999, 76:448\u2013460.","journal-title":"J Urban Health"},{"key":"20_CR54","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/oxfordjournals.aje.a009240","volume":"146","author":"J Bruneau","year":"1997","unstructured":"Bruneau J, Lamothe F, Franco E, et al.: High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study. Am J Epidemiol 1997, 146:994\u20131002.","journal-title":"Am J Epidemiol"},{"key":"20_CR55","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF02350966","volume":"77","author":"H Hagan","year":"2000","unstructured":"Hagan H, McGough JP, Thiede H, et al.: Volunteer bias in nonrandomized evaluations of the efficacy of needle-exchange programs. J Urban Health 2000, 77:103\u2013112.","journal-title":"J Urban Health"},{"key":"20_CR56","doi-asserted-by":"crossref","first-page":"F45","DOI":"10.1097\/00002030-199904160-00002","volume":"13","author":"MT Schechter","year":"1999","unstructured":"Schechter MT, Strathdee SA, Cornelisse PG, et al.: Do needle exchange programmes increase the spread of HIV among injection drug users? An investigation of the Vancouver outbreak. AIDS 1999, 13:F45-F51.","journal-title":"AIDS"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-004-0020-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11920-004-0020-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-004-0020-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:41:03Z","timestamp":1559436063000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11920-004-0020-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["20"],"URL":"https:\/\/doi.org\/10.1007\/s11920-004-0020-1","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}